Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma

Scott E. Eggener, Ofer Yossepowitch, Shilajit Kundu, Robert J. Motzer, Paul Russo*

*Corresponding author for this work

Research output: Contribution to journalArticle

84 Citations (Scopus)

Abstract

Purpose: We evaluated the prognostic roles of metastasectomy and an established risk stratification system in patients with disease recurrence following nephrectomy for nonmetastatic renal cell carcinoma. Materials and Methods: A retrospective analysis was performed in 129 patients with localized renal cell carcinoma treated with partial or radical nephrectomy and subsequently diagnosed with disease recurrence. At recurrence a previously validated risk score based on Karnofsky performance status, interval from nephrectomy, and serum hemoglobin, calcium and lactate dehydrogenase was used to categorize patients as being at favorable, intermediate or poor risk. Survival from time of recurrence was assessed based on risk categorization and metastasectomy. Results: Median time from nephrectomy to recurrence was 16 months. The risk score was strongly associated with median survival and the 2-year survival rate, including 73 months and 81% for favorable risk, 28 months and 54% for intermediate risk, and 6 months and 11% for poor risk, respectively (log rank <0.001). Metastasectomy performed in 44 patients (34%) was found to be of clinical benefit across the various risk categories (interaction analysis p = 0.8). On multivariate analysis a better risk category and metastasectomy were each independently associated with more favorable survival (each p <0.001). When combined, they provided 6 risk categories with an estimated 2-year survival of 0% to 93%. Conclusions: The clinical course in patients with recurrent renal cell carcinoma following nephrectomy can be variable. It is independently impacted by an objectively determined risk score and whether the patient undergoes metastasectomy.

Original languageEnglish (US)
Pages (from-to)873-878
Number of pages6
JournalJournal of Urology
Volume180
Issue number3
DOIs
StatePublished - Sep 1 2008

Fingerprint

Metastasectomy
Renal Cell Carcinoma
Nephrectomy
Recurrence
Survival
Karnofsky Performance Status
L-Lactate Dehydrogenase

Keywords

  • carcinoma
  • kidney
  • local
  • neoplasm metastasis
  • neoplasm recurrence
  • nephrectomy
  • renal cell

ASJC Scopus subject areas

  • Urology

Cite this

Eggener, Scott E. ; Yossepowitch, Ofer ; Kundu, Shilajit ; Motzer, Robert J. ; Russo, Paul. / Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma. In: Journal of Urology. 2008 ; Vol. 180, No. 3. pp. 873-878.
@article{3980135f55d84b039598af196fb3380f,
title = "Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma",
abstract = "Purpose: We evaluated the prognostic roles of metastasectomy and an established risk stratification system in patients with disease recurrence following nephrectomy for nonmetastatic renal cell carcinoma. Materials and Methods: A retrospective analysis was performed in 129 patients with localized renal cell carcinoma treated with partial or radical nephrectomy and subsequently diagnosed with disease recurrence. At recurrence a previously validated risk score based on Karnofsky performance status, interval from nephrectomy, and serum hemoglobin, calcium and lactate dehydrogenase was used to categorize patients as being at favorable, intermediate or poor risk. Survival from time of recurrence was assessed based on risk categorization and metastasectomy. Results: Median time from nephrectomy to recurrence was 16 months. The risk score was strongly associated with median survival and the 2-year survival rate, including 73 months and 81{\%} for favorable risk, 28 months and 54{\%} for intermediate risk, and 6 months and 11{\%} for poor risk, respectively (log rank <0.001). Metastasectomy performed in 44 patients (34{\%}) was found to be of clinical benefit across the various risk categories (interaction analysis p = 0.8). On multivariate analysis a better risk category and metastasectomy were each independently associated with more favorable survival (each p <0.001). When combined, they provided 6 risk categories with an estimated 2-year survival of 0{\%} to 93{\%}. Conclusions: The clinical course in patients with recurrent renal cell carcinoma following nephrectomy can be variable. It is independently impacted by an objectively determined risk score and whether the patient undergoes metastasectomy.",
keywords = "carcinoma, kidney, local, neoplasm metastasis, neoplasm recurrence, nephrectomy, renal cell",
author = "Eggener, {Scott E.} and Ofer Yossepowitch and Shilajit Kundu and Motzer, {Robert J.} and Paul Russo",
year = "2008",
month = "9",
day = "1",
doi = "10.1016/j.juro.2008.05.006",
language = "English (US)",
volume = "180",
pages = "873--878",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "3",

}

Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma. / Eggener, Scott E.; Yossepowitch, Ofer; Kundu, Shilajit; Motzer, Robert J.; Russo, Paul.

In: Journal of Urology, Vol. 180, No. 3, 01.09.2008, p. 873-878.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Risk Score and Metastasectomy Independently Impact Prognosis of Patients With Recurrent Renal Cell Carcinoma

AU - Eggener, Scott E.

AU - Yossepowitch, Ofer

AU - Kundu, Shilajit

AU - Motzer, Robert J.

AU - Russo, Paul

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Purpose: We evaluated the prognostic roles of metastasectomy and an established risk stratification system in patients with disease recurrence following nephrectomy for nonmetastatic renal cell carcinoma. Materials and Methods: A retrospective analysis was performed in 129 patients with localized renal cell carcinoma treated with partial or radical nephrectomy and subsequently diagnosed with disease recurrence. At recurrence a previously validated risk score based on Karnofsky performance status, interval from nephrectomy, and serum hemoglobin, calcium and lactate dehydrogenase was used to categorize patients as being at favorable, intermediate or poor risk. Survival from time of recurrence was assessed based on risk categorization and metastasectomy. Results: Median time from nephrectomy to recurrence was 16 months. The risk score was strongly associated with median survival and the 2-year survival rate, including 73 months and 81% for favorable risk, 28 months and 54% for intermediate risk, and 6 months and 11% for poor risk, respectively (log rank <0.001). Metastasectomy performed in 44 patients (34%) was found to be of clinical benefit across the various risk categories (interaction analysis p = 0.8). On multivariate analysis a better risk category and metastasectomy were each independently associated with more favorable survival (each p <0.001). When combined, they provided 6 risk categories with an estimated 2-year survival of 0% to 93%. Conclusions: The clinical course in patients with recurrent renal cell carcinoma following nephrectomy can be variable. It is independently impacted by an objectively determined risk score and whether the patient undergoes metastasectomy.

AB - Purpose: We evaluated the prognostic roles of metastasectomy and an established risk stratification system in patients with disease recurrence following nephrectomy for nonmetastatic renal cell carcinoma. Materials and Methods: A retrospective analysis was performed in 129 patients with localized renal cell carcinoma treated with partial or radical nephrectomy and subsequently diagnosed with disease recurrence. At recurrence a previously validated risk score based on Karnofsky performance status, interval from nephrectomy, and serum hemoglobin, calcium and lactate dehydrogenase was used to categorize patients as being at favorable, intermediate or poor risk. Survival from time of recurrence was assessed based on risk categorization and metastasectomy. Results: Median time from nephrectomy to recurrence was 16 months. The risk score was strongly associated with median survival and the 2-year survival rate, including 73 months and 81% for favorable risk, 28 months and 54% for intermediate risk, and 6 months and 11% for poor risk, respectively (log rank <0.001). Metastasectomy performed in 44 patients (34%) was found to be of clinical benefit across the various risk categories (interaction analysis p = 0.8). On multivariate analysis a better risk category and metastasectomy were each independently associated with more favorable survival (each p <0.001). When combined, they provided 6 risk categories with an estimated 2-year survival of 0% to 93%. Conclusions: The clinical course in patients with recurrent renal cell carcinoma following nephrectomy can be variable. It is independently impacted by an objectively determined risk score and whether the patient undergoes metastasectomy.

KW - carcinoma

KW - kidney

KW - local

KW - neoplasm metastasis

KW - neoplasm recurrence

KW - nephrectomy

KW - renal cell

UR - http://www.scopus.com/inward/record.url?scp=48649103682&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=48649103682&partnerID=8YFLogxK

U2 - 10.1016/j.juro.2008.05.006

DO - 10.1016/j.juro.2008.05.006

M3 - Article

VL - 180

SP - 873

EP - 878

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 3

ER -